• FDA Warns of Liver Injury with Mavyret, Zepatier, Vosevi americanpharmaceuticalreview
    September 03, 2019
    The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases...
PharmaSources Customer Service